The Glaucoma and Retinopathy Screening Study
Recruiting · NCT06882356 · Interventional (participants receive a specific treatment) · Lead sponsor: Massachusetts Eye and Ear Infirmary
View the official record on ClinicalTrials.gov →Interventions studied
AI-based glaucoma screeningIOP measurementVirtual Reality Visual Field Testing
What this trial is about
The goal of this clinical trial is to learn if a new screening approach including an artificial intelligence algorithm that analyzes fundus photographs, measurement of eye pressure and visual field testing works to screen for glaucoma. Participants will: Have an image of their fundus (back of the eye) taken as part of their diabetic eye screening Have a measurement of their eye pressure If needed, have a test of their side vision using a headset
Who can take part
Age range
40 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Eligibility criteria (as published)
* Individuals with diabetes undergoing AI-based screening for diabetic retinopathy using the LumineticsCore (Digital Diagnostics) system at primary care centers.
* Individuals who are able and willing to provide informed consent for participation in the study.
Where it is running
7 locations listed across 1 US state.
- Massachusetts General Hospital Internal Medicine Associates - Boston, Massachusetts, United States
- Brigham and Women's Primary Care Associates of Longwood - Boston, Massachusetts, United States
- Massachusetts General Hospital Broadway Primary Care-Revere - Boston, Massachusetts, United States
- MGH Chelsea HealthCare Center - Chelsea, Massachusetts, United States
- NSPG Lynn - Lynn, Massachusetts, United States
- NSPG Salem - Salem, Massachusetts, United States
- NSPG Saugus - Saugus, Massachusetts, United States